Flippin Bruce & Porter Raised Cvs Health (CVS) Holding By $3.28 Million; Shorts at Karyopharm Therapeutics (KPTI) Raised By 13.48%

May 26, 2018 - By Ash

CVS Health Corporation (NYSE:CVS) Logo

Karyopharm Therapeutics Inc (NASDAQ:KPTI) had an increase of 13.48% in short interest. KPTI’s SI was 2.36 million shares in May as released by FINRA. Its up 13.48% from 2.08M shares previously. With 512,300 avg volume, 5 days are for Karyopharm Therapeutics Inc (NASDAQ:KPTI)’s short sellers to cover KPTI’s short positions. The SI to Karyopharm Therapeutics Inc’s float is 7.16%. The stock increased 1.96% or $0.34 during the last trading session, reaching $17.68. About 643,941 shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 23.92% since May 26, 2017 and is uptrending. It has outperformed by 12.37% the S&P500.

Flippin Bruce & Porter Inc increased Cvs Health Corp (CVS) stake by 53.79% reported in 2017Q4 SEC filing. Flippin Bruce & Porter Inc acquired 45,519 shares as Cvs Health Corp (CVS)’s stock declined 17.45%. The Flippin Bruce & Porter Inc holds 130,149 shares with $9.44M value, up from 84,630 last quarter. Cvs Health Corp now has $67.13B valuation. The stock increased 1.40% or $0.91 during the last trading session, reaching $66.03. About 5.56 million shares traded. CVS Health Corporation (NYSE:CVS) has declined 22.81% since May 26, 2017 and is downtrending. It has underperformed by 34.36% the S&P500.

Since December 11, 2017, it had 0 insider purchases, and 31 sales for $3.58 million activity. The insider Shacham Sharon sold 10,000 shares worth $193,870. Primiano Christopher Brett sold $37,527 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Thursday, February 15. Kauffman Michael had sold 10,000 shares worth $100,882 on Thursday, January 18. 1,500 shares valued at $19,500 were sold by Mirza Mansoor Raza on Wednesday, February 7.

Investors sentiment decreased to 1.56 in Q4 2017. Its down 0.94, from 2.5 in 2017Q3. It worsened, as 4 investors sold Karyopharm Therapeutics Inc. shares while 21 reduced holdings. 11 funds opened positions while 28 raised stakes. 30.26 million shares or 8.41% more from 27.91 million shares in 2017Q3 were reported. California State Teachers Retirement Systems stated it has 53,278 shares or 0% of all its holdings. Jacobs Levy Equity Mngmt holds 0.01% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 53,200 shares. 3,000 were accumulated by Sandy Spring National Bank. Northern owns 0% invested in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 385,717 shares. Schwab Charles Mgmt Inc accumulated 150,289 shares. Proshare Advsr Ltd Liability reported 30,437 shares stake. Point72 Asset Mngmt Ltd Partnership stated it has 3.35M shares or 0.14% of all its holdings. Bankshares Of New York Mellon holds 0% or 163,093 shares in its portfolio. Alliancebernstein Ltd Partnership has 118,430 shares. 26,000 are held by State Of Wisconsin Investment Board. Parallax Volatility Advisers Ltd Partnership stated it has 5,124 shares or 0% of all its holdings. Swiss National Bank holds 0% or 56,850 shares in its portfolio. Iguana Healthcare Mgmt Ltd Llc holds 300,000 shares or 1.88% of its portfolio. Thomas J Herzfeld Advisors, Florida-based fund reported 1,500 shares. Dimensional Fund Lp invested in 0% or 315,890 shares.

More notable recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: Seekingalpha.com which released: “Karyopharm Impresses In Refractory Multiple Myeloma Trial” on May 01, 2018, also Benzinga.com with their article: “The Week Ahead In Biotech: ASCO Presentations In The Spotlight” published on May 26, 2018, Seekingalpha.com published: “Your Daily Pharma Scoop: KPTI Data, Allergan Write-Off, Celgene Down On Delay” on May 02, 2018. More interesting news about Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on May 24, 2018 as well as Globenewswire.com‘s news article titled: “Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock” with publication date: May 03, 2018.

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 11 have Buy rating, 1 Sell and 1 Hold. Therefore 85% are positive. Karyopharm Therapeutics Inc. had 39 analyst reports since August 11, 2015 according to SRatingsIntel. On Thursday, May 24 the stock rating was downgraded by Wedbush to “Neutral”. H.C. Wainwright reinitiated the shares of KPTI in report on Wednesday, November 15 with “Buy” rating. On Friday, May 27 the stock rating was initiated by Raymond James with “Outperform”. As per Tuesday, August 30, the company rating was upgraded by Jefferies. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by RBC Capital Markets on Monday, October 16. H.C. Wainwright initiated the shares of KPTI in report on Thursday, August 18 with “Buy” rating. The rating was downgraded by Bank of America on Tuesday, March 15 to “Underperform”. As per Tuesday, May 15, the company rating was maintained by Canaccord Genuity. Jefferies maintained the shares of KPTI in report on Monday, September 11 with “Buy” rating. The firm has “Buy” rating by Canaccord Genuity given on Monday, March 12.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $1.06 billion. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Investors sentiment decreased to 0.72 in Q4 2017. Its down 0.16, from 0.88 in 2017Q3. It is negative, as 115 investors sold CVS shares while 600 reduced holdings. 134 funds opened positions while 380 raised stakes. 815.59 million shares or 1.76% more from 801.45 million shares in 2017Q3 were reported. Verity & Verity Ltd Liability has 88,115 shares. Johnson Fincl Group reported 21,583 shares or 0.19% of all its holdings. Mai Cap Mgmt invested in 0.38% or 92,924 shares. Thompson Inv reported 1.17% stake. Bluemountain Cap Ltd Liability Corp has invested 0.26% of its portfolio in CVS Health Corporation (NYSE:CVS). Front Barnett Assocs Limited Liability accumulated 33,212 shares. 352,530 were reported by Fiduciary Trust. Highland Capital Management Limited Liability Corp invested in 45,841 shares. Visionary Asset Management Inc has invested 0.07% in CVS Health Corporation (NYSE:CVS). Edgar Lomax Va owns 648,108 shares for 3.21% of their portfolio. Reliance Tru Company Of Delaware holds 0.47% or 42,568 shares in its portfolio. Dillon & Associates stated it has 0.12% in CVS Health Corporation (NYSE:CVS). Sumitomo Mitsui Hldg stated it has 2.93 million shares. Asset has invested 0.09% in CVS Health Corporation (NYSE:CVS). Millennium Mngmt Ltd Company accumulated 1.04 million shares.

More notable recent CVS Health Corporation (NYSE:CVS) news were published by: Seekingalpha.com which released: “We Are Playing The CVS Hand” on May 11, 2018, also Seekingalpha.com with their article: “Trade Mistake 3: CVS Boredom Trade” published on May 09, 2018, Fool.com published: “5 Things You’ll Want to Know About CVS Health’s Plans for 2018 and Beyond” on May 04, 2018. More interesting news about CVS Health Corporation (NYSE:CVS) were released by: Seekingalpha.com and their article: “CVS: Going Long, And Understanding The Aetna Deal” published on April 30, 2018 as well as 247Wallst.com‘s news article titled: “Alibaba, CVS, Tesla and Other Earnings to Watch For This Week” with publication date: April 29, 2018.

Among 26 analysts covering CVS Health (NYSE:CVS), 19 have Buy rating, 0 Sell and 7 Hold. Therefore 73% are positive. CVS Health had 77 analyst reports since July 22, 2015 according to SRatingsIntel. Robert W. Baird maintained it with “Hold” rating and $80.0 target in Thursday, February 8 report. Morgan Stanley upgraded the stock to “Overweight” rating in Friday, January 5 report. SunTrust maintained the stock with “Buy” rating in Friday, October 13 report. The stock of CVS Health Corporation (NYSE:CVS) has “Hold” rating given on Wednesday, August 16 by Wolfe Research. RBC Capital Markets maintained it with “Buy” rating and $89.0 target in Thursday, February 8 report. Robert W. Baird maintained the shares of CVS in report on Friday, October 27 with “Hold” rating. As per Thursday, August 17, the company rating was maintained by Citigroup. Leerink Swann maintained it with “Buy” rating and $8500 target in Tuesday, April 10 report. On Wednesday, October 18 the stock rating was maintained by Jefferies with “Hold”. The firm has “Hold” rating given on Thursday, January 4 by Robert W. Baird.

Flippin Bruce & Porter Inc decreased Apple Inc (NASDAQ:AAPL) stake by 33,649 shares to 63,933 valued at $10.82 million in 2017Q4. It also reduced Ford Mtr Co (NYSE:F) stake by 26,199 shares and now owns 642,421 shares. Target Corp (NYSE:TGT) was reduced too.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: